NCT05806814Active, not recruitingPhase 1
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 28 Mar 2023
- Start date
- 12 Nov 2023
- Primary completion date
- 13 May 2026
- Lead sponsor
- University of Oklahoma
- Diseases
- Prostate cancer
- NCT number
- NCT05806814
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 15
- From 12 Nov 2023 to the primary completion date, 13 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received Sipuleucel-T (Provenge®)
- A requirement for systemic immunosuppressive therapy (\>10mg Prednisone daily or equivalent)
- Any infection requiring antibiotic therapy within 1 week prior to registration
Other illness
- Known malignancies other than prostate cancer likely to require treatment within 6 months following registration
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sipuleucel-T or GM-CSF
Who the study is looking for
- Men ≥ 18 years of age
- Prostate cancer with history of metastasis
- Candidates for Sipuleucel-T treatment are defined as those with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of ≥ 6 months
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Oklahoma Health Sciences Center, Stephenson Cancer Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.